secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001193125-24-262615
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica launches underwritten public offering of common stock and warrants
--------------------------------------------------------------------------

- Offering of common stock (or pre-funded warrants) and accompanying warrants; Jefferies sole bookrunner; 30-day option for 15% additional.
- Terminated ATM equity prospectus; no shares had been issued under the Open Market Sales Agreement with Jefferies.
- Targeting monthly operating cash flow break-even in H2 2025 after restructuring sales force from 80 to ~33 territories.
- Phase 2 data for VP-315 in BCC: 86% tumor size reduction, 51% complete histological clearance (n=90); End-of-Phase 2 meeting planned H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524262615/0001193125-24-262615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524262615/d907739d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-262615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer